Eugène McFadden

Active 1991–2025

75
Papers
22,761
Citations
65
h-index
73
i10-index

Citations

Citations per year for Eugène McFadden1991: 4 citations1992: 1 citations1993: 5 citations1994: 6 citations1995: 6 citations1996: 18 citations1997: 6 citations1998: 13 citations1999: 30 citations2000: 53 citations2001: 32 citations2002: 31 citations2003: 33 citations2004: 56 citations2005: 178 citations2006: 304 citations2007: 341 citations2008: 209 citations2009: 187 citations2010: 161 citations2011: 192 citations2012: 140 citations2013: 151 citations2014: 94 citations2015: 103 citations2016: 76 citations2017: 61 citations2018: 56 citations2019: 280 citations2020: 348 citations2021: 284 citations2022: 271 citations2023: 218 citations2024: 346 citations2025: 167 citations2026: 8 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,327 citing papers, 17.1% of this breakdownItaly: 655 citing papers, 8.4% of this breakdownNetherlands: 619 citing papers, 8% of this breakdownGermany: 567 citing papers, 7.3% of this breakdownUnited Kingdom: 534 citing papers, 6.9% of this breakdownSwitzerland: 369 citing papers, 4.7% of this breakdownFrance: 359 citing papers, 4.6% of this breakdownJapan: 344 citing papers, 4.4% of this breakdownChina: 295 citing papers, 3.8% of this breakdownSouth Korea: 280 citing papers, 3.6% of this breakdownSpain: 260 citing papers, 3.3% of this breakdownBelgium: 251 citing papers, 3.2% of this breakdown
0%17.1%Other 24.7%

Fields

  • Medicine93.4%
  • Biochemistry, Genetics and Molecular Biology2.7%
  • Materials Science1.3%
  • Engineering1.2%
  • Immunology and Microbiology0.2%
  • Computer Science0.2%
  • Other1%

Topics

  • Coronary Interventions and Diagnostics20.8%
  • Cardiac Imaging and Diagnostics11.7%
  • Acute Myocardial Infarction Research10.3%
  • Antiplatelet Therapy and Cardiovascular Diseases9.6%
  • Peripheral Artery Disease Management3.5%
  • Atrial Fibrillation Management and Outcomes3%
  • Other41.1%

Coauthors

All papers

Open in search
  1. Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document

    Authors: , , , , , , , , , , , , , , , , , - Circulation 2018 cited by 933

  2. Clinical End Points in Coronary Stent Trials

    Authors: , , , , , , , , , , , , , , - Circulation 2007 cited by 5,420

  3. P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Journal of the American College of Cardiology 2023 cited by 177

  4. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Richard Anderson, Rick Andreae, Michaël Angioı̈, Taku Asano, Emanuele Barbato, Peter Barlis, Pascal Barraud, Edouard Benit, Olivier F. Bertrand, Farzin Beygui, Leonardo Bolognese, Roberto Botelho, Coby Bouwman, Marco Bressers, Philippe Brunel, Paweł Buszman, Ian Buysschaert, Pedro Canas da Silva, Didier Carrié, Ángel Cequier, Ply Chichareon, Chun Chin Chang, Saqib Chowdhary, Carlos Collet, Antonio Colombo, James Cotton, Rui Cruz Ferreira, Salvatore Curello, Nick Curzen, Judith de Bot, Tone de Vreede, Georg Delle Karth, Lynn Dijksma, Marcello Dominici, István Édes, Éric Eeckhout, Ingo Eitel, József Faluközy, Farzin Fath‐Ordoubadi, Maurizio Ferrario, Géza Fontos, José Francisco Díaz Fernández, Edgard Freitas Quintella, Bernhard Frey, Guy Friedrich, Gavin Galasko, G. Gałuszka, Vasco Gama Ribeiro, Scot Garg, Giuseppe Gargiulo, Tobias Geisler, Валери Гелев, Art Ghandilyan, Javier Goicolea, Tommaso Gori, Felice Gragnano, Ana Guimarães, Christian W. Hamm, Michael Haude, Dik Heg, Pieter Heijke, Rosa Ana Hernández Antolín, David Hildick‐Smith, Dorien Hillen, Ina Hoekman, Sjoerd H. Hofma, Lene Holmvang, Stephen P. Hoole, Iván Horváth, Kurt Huber and 103 more - The Lancet 2018 cited by 785

  5. Standardized End Point Definitions for Coronary Intervention Trials

    Authors: , , , , , , , , , , , , , , , , , - European Heart Journal 2018 cited by 311

  6. P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - BMJ 2021 cited by 255

  7. Ticagrelor or Clopidogrel Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - JAMA Cardiology 2024 cited by 86

  8. Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Marco Valgimigli - Journal of the American College of Cardiology 2019 cited by 148

  9. De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2024 cited by 95

  10. P2Y12 Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary Interventions

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of the American College of Cardiology 2023 cited by 119

  11. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy

    Authors: , , , , , , , , , , , , , - The Lancet 2004 cited by 1,437

  12. Abbreviated or Standard Dual Antiplatelet Therapy by Sex in Patients at High Bleeding Risk

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Marie‐Claude Morice, Stephan Windecker, Yoshinobu Onuma, Enrico Frigoli, Andrè Frenk, Peter C. Jüni, Jan G.P. Tijssen, Dragica Paunovic, Mullasari S. Ajit, Mirvat Alasnag, Jozef Bartúnek, Antonio Colombo, David Hildick‐Smith, Andrés Íñiguez, Felix Mahfoud, Ran Kornowski, Maciej Lesiak, Paul Jau Lueng Ong, Alfredo E. Rodríguez, Marco Roffi, Carl Schultz, Goran Stanković, Pim A.L. Tonino, Aris Moschovitis, Peep Laanmets, Michael Donahue, M Bertrand, Stuart Pocock, Philip Urban, Sergio Leonardi, Claude Hanet, Renato D. Lópes, Eugène McFadden, Peter W. Radke, Risto O. Roine, Boudijn Ladan, Laura van der Waal, Yvonne Engelbrecht, Fred Paddenburg, Ben Ren, Ingrid de Zwart, Liliane Elshout, Judith Jonk, Tessa Rademaker‐Havinga, Ria van Vliet, Phani Krishna Kondamudi, Laure Morsiani, U. Windhövel, Anita van der Wal, C.D. Bakker, Kazuhiro Minagawa, Juan Mieres, Fernando Cura, Carlos Fernández‐Pereira, A. Lee, Nigel Jepson, Robert Whitbourn, Owen Christopher Raffel, Kurt Huber, Franz Weidinger, Fazila-Tun-Nesa Malik Hasselt, Jessa Ziekenhuis, Imelda Ziekenhuis, Willem Dewilde, Adel Aminian, Emanuele Aalst, Suzanne Pourbaix, Panagiotis Xaplanteris, Vasil Velchev, Dimitar Karageorgiev and 109 more - JAMA Cardiology 2023 cited by 30

  13. Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jeffrey W. Moses, David M. Greer, John K. Forrest, David R. Holmes, A. Pieter Kappetein, Michael J. Mack, Andreas Baumbach - European Heart Journal 2017 cited by 158

  14. Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - European Heart Journal 2018 cited by 93

  15. PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSY

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Peter Jüni, Stephan Windecker, Marco Valgimigli - European Heart Journal - Cardiovascular Pharmacotherapy 2020 cited by 63

  16. Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Samantha Sartori, Brian Kirkham, Javier Escaned, Dik Heg, Stephan Windecker, Stuart Pocock, Peter Jüni, Marco Valgimigli, Roxana Mehran, Stephan Windecker, Pascal Vranckx, Patrick W. Serruys, Gabriel P. Steg, Christian W. Hamm, Usman Baber, Dominick J. Angiolillo, David J. Cohen, George Dangas, Shamir R. Mehta, Michael C. Gibson, Adnan Kastrati, Mitchel Krucoff, Magnus Öhman, Paul A. Gurbel, Timothy D. Henry, David J. Moliterno, Samin K. Sharma, Stuart Pocock, Peter Jüni, Bruno R. da Costa, Brian Kirkham, Samantha Sartori, Dierik Heg, Eugène McFadden, Sergio Leonardi, Raffaele Piccolo, Anna Franzone, Steven O. Marx, Bruce Darrow, Nicola Corvaja, Douglas DeStefano, Newsha Ghodsi, Jose Meller, Theresa Franklin-Bond, Jin Young, Zaha Waseem, Peter Jüni, Bruno R. da Costa, Brian Kirkham, Kurt Huber, Giora Weisz, Ran Kornowski, Vijay Kunadian, Keith G. Oldroyd, Yaling Han, Upendra Kaul, Bernhard Witzenbichler, Vladimír Džavík, Robert Gil, Dariuz Dudek, Gennaro Sardella, Javier Escaned, Richard Shlofmitz, Carlo Briguori, Edouard Benit, Christoph Liebetrau, Luc Janssens, Maurizio Ferrario, Aleksander Żurakowski, Roberto Diletti and 16 more - JACC: Cardiovascular Interventions 2021 cited by 37

  17. Endothelial Progenitor Cell Capture by Stents Coated With Antibody Against CD34

    Authors: , , , , , , , , , , , - Journal of the American College of Cardiology 2005 cited by 545

  18. Value of preprocedure multislice computed tomographic coronary angiography to predict the outcome of percutaneous recanalization of chronic total occlusions

    Authors: , , , , , , , , - The American Journal of Cardiology 2005 cited by 194

  19. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation

    Authors: , , , , , , , , , - European Heart Journal 2005 cited by 386

  20. Zotarolimus-Eluting Versus Bare-Metal Stents in Uncertain Drug-Eluting Stent Candidates

    Authors: , , , , , , , , , , , , , , , , , , , , , - Journal of the American College of Cardiology 2015 cited by 279

  21. Impact of Periprocedural Myocardial Biomarker Elevation on Mortality Following Elective Percutaneous Coronary Intervention

    Authors: , , , , , , , , , , , , , , , , , - JACC: Cardiovascular Interventions 2019 cited by 66

  22. High-Resolution Spiral Computed Tomography Coronary Angiography in Patients Referred for Diagnostic Conventional Coronary Angiography

    Authors: , , , , , , , , - Circulation 2005 cited by 1,015

  23. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial

    Authors: , , , , , , - The Lancet 2010 cited by 687

  24. Randomized Multicenter Comparison of Conventional Anticoagulation Versus Antiplatelet Therapy in Unplanned and Elective Coronary Stenting

    Authors: , , , , , , , , , , , , , , , - Circulation 1998 cited by 584